Methods of microbial treatment of poultry
Disclosed are methods of administering one or more Bacillus strains to poultry. The Bacillus strains improve bacterial homeostasis in the gastrointestinal tract by inhibiting bacterial pathogens such as E. coli and Clostridium . Administering the Bacillus strains also improves performance such as weight gain and feed conversion. Useful combinations of Bacillus strains and methods of using one or more Bacillus strains are also provided.
1. A method for inhibiting a pathogen in an avian animal, said method comprising administering to an animal an effective amount of at least one isolated Bacillus strain chosen from the strains B. subtilis 747, deposited as NRRL B-67257; B. subtilis 1104, deposited as NRRL B-67258; B. subtilis 1781, deposited as NRRL B-67259; B. subtilis 1541, deposited as NRRL B-67260; and B. subtilis 2018, deposited as NRRL B-67261, wherein said administration inhibits a pathogen chosen from at least one of E. coli and Clostridium in the animal.
2. The method of claim 1 , wherein the animal is a chicken.
3. The method of claim 1 , wherein the animal is a turkey.
4. The method of claim 1 , wherein administering said strain or strains to said avian animal improves average daily weight gain relative to that in avian animals that have not been administered the strain or strains.
5. The method of claim 1 , wherein administering said strain or strains to a first group of said avian animals decreases mortality rate amongst the group of avian animals relative to that in second group of avian animals that have not been administered the strain or strains.
6. The method of claim 1 , wherein administering said strain or strains to said avian animal reduces a level of C. perfringens Type A in gastrointestinal tract tissue of the avian animal relative to that in avian animals that have not been administered the strain or strains.
7. The method of claim 6 , wherein the level of C. perfringens Type A in in avian animals is reduced by about 85.0% relative to that in animals that have not been administered the strain or strains.
8. The method of claim 6 , wherein the level of C. perfringens Type A in gastrointestinal tract tissue of the avian animals is less than 50 CFU/g following treatment with said strain or strains.
9. The method of claim 6 , wherein the occurrence of necrotic enteritis in the avian animal is reduced relative to that in avian animals that have not been administered the strain or strains.
10. The method of claim 1 , wherein administering said strain or strains to an avian animal reduces a level of avian pathogenic E. coli (APEC) in gastrointestinal tract tissue of the avian animal relative to that in avian animals that have not been administered the strain or strains.
11. The method of claim 10 , wherein the level of avian pathogenic E. coli (APEC) in the avian animal is reduced by about 80.0%.
12. The method of claim 10 , wherein administering said strain or strains to the avian animal reduces the level of colibacillosis in the avian animal relative to that in avian animals that have not been administered the strain or strains.
13. The method of claim 1 , wherein the method comprises administering to the avian animal an effective amount of a plurality of isolated Bacillus strains chosen from the strains B. subtilis 747, deposited as NRRL B-67257; B. subtilis 1104, deposited as NRRL B-67258; B. subtilis 1781, deposited as NRRL B-67259; B. subtilis 1541 deposited as NRRL B-67260; and B. subtilis 2018, deposited as NRRL B-67261 to inhibit a pathogen chosen from at least one of E. coli and Clostridium in the animal.
14. The method of claim 1 , wherein the effective amount of plurality of isolated Bacillus strains are administered to the avian animal in a direct fed microbial composition; wherein the composition further comprises a carrier.
15. The method of claim 1 , wherein administering an effective amount of a plurality of isolated Bacillus strains to the avian animal modulates the immune system of the avian animal.